Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Business
DSM Scores NicOx Ingredient Contract
by Lisa M. Jarvis
December 8, 2008
| A version of this story appeared in
Volume 86, Issue 49
DSM has won a contract to make commercial quantities of the active pharmaceutical ingredient (API) for NicOx's lead drug candidate, naproxcinod. The French biotech firm expects to submit a New Drug Application to use naproxcinod in osteoarthritis in mid-2009 and says DSM will likely deliver the first batch of the API from Linz, Austria, late next year. Archimica had supplied the API for clinical trials, but NicOx decided to go with DSM for commercial production on the basis of cost considerations.
You might also like...
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X